JP2015520769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520769A5 JP2015520769A5 JP2015514535A JP2015514535A JP2015520769A5 JP 2015520769 A5 JP2015520769 A5 JP 2015520769A5 JP 2015514535 A JP2015514535 A JP 2015514535A JP 2015514535 A JP2015514535 A JP 2015514535A JP 2015520769 A5 JP2015520769 A5 JP 2015520769A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituents
- independently selected
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 112
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- 229920006395 saturated elastomer Polymers 0.000 claims description 66
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 229910052717 sulfur Inorganic materials 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 125000001624 naphthyl group Chemical group 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 30
- 125000005842 heteroatom Chemical group 0.000 claims description 30
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000004429 atom Chemical group 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 229940124530 sulfonamide Drugs 0.000 claims description 18
- 150000003456 sulfonamides Chemical class 0.000 claims description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
- 150000003573 thiols Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 230000000495 immunoinflammatory effect Effects 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000001326 naphthylalkyl group Chemical group 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 3
- 0 CC(CC(c1ccccc1)=O)=C(C=CC=C1)C1=CC(SCCN(C)C)=** Chemical compound CC(CC(c1ccccc1)=O)=C(C=CC=C1)C1=CC(SCCN(C)C)=** 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- XDZBDLYXHMKEPU-UHFFFAOYSA-N Fc1cc(NCc2nc(OCCN3CCCCC3)cc3c2cccc3)cc(F)c1 Chemical compound Fc1cc(NCc2nc(OCCN3CCCCC3)cc3c2cccc3)cc(F)c1 XDZBDLYXHMKEPU-UHFFFAOYSA-N 0.000 description 1
- SOVOWYHTJTWTFL-UHFFFAOYSA-N NCCCc1cc(cccc2)c2c(NC=O)n1 Chemical compound NCCCc1cc(cccc2)c2c(NC=O)n1 SOVOWYHTJTWTFL-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YOEBCMBOBHLGML-UHFFFAOYSA-N O=C(Cc1nc(SCCN2CCCCC2)cc2c1cccc2)c1cc(F)cc(F)c1 Chemical compound O=C(Cc1nc(SCCN2CCCCC2)cc2c1cccc2)c1cc(F)cc(F)c1 YOEBCMBOBHLGML-UHFFFAOYSA-N 0.000 description 1
- ASZRNYIGTQIFJA-UHFFFAOYSA-N O=C(c1ccccc1)Nc1nc(CCCN2CCCC2)cc2c1cccc2 Chemical compound O=C(c1ccccc1)Nc1nc(CCCN2CCCC2)cc2c1cccc2 ASZRNYIGTQIFJA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654385P | 2012-06-01 | 2012-06-01 | |
| US61/654,385 | 2012-06-01 | ||
| PCT/EP2013/061330 WO2013178816A1 (en) | 2012-06-01 | 2013-05-31 | Heterocycles capable of modulating t-cell responses, and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520769A JP2015520769A (ja) | 2015-07-23 |
| JP2015520769A5 true JP2015520769A5 (enExample) | 2016-07-21 |
| JP6167173B2 JP6167173B2 (ja) | 2017-07-19 |
Family
ID=48538006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514535A Expired - Fee Related JP6167173B2 (ja) | 2012-06-01 | 2013-05-31 | Ｔ細胞受容体を調節することができる複素環およびそれを使用するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9013997B2 (enExample) |
| EP (1) | EP2861575B1 (enExample) |
| JP (1) | JP6167173B2 (enExample) |
| KR (1) | KR102181914B1 (enExample) |
| CN (1) | CN104619691B (enExample) |
| AU (1) | AU2013269551B2 (enExample) |
| BR (1) | BR112014030050A2 (enExample) |
| CA (1) | CA2874938C (enExample) |
| CY (1) | CY1122203T1 (enExample) |
| DK (1) | DK2861575T3 (enExample) |
| ES (1) | ES2726109T3 (enExample) |
| HR (1) | HRP20190764T1 (enExample) |
| HU (1) | HUE043201T2 (enExample) |
| LT (1) | LT2861575T (enExample) |
| MX (1) | MX366205B (enExample) |
| PL (1) | PL2861575T3 (enExample) |
| PT (1) | PT2861575T (enExample) |
| SI (1) | SI2861575T1 (enExample) |
| WO (1) | WO2013178816A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| HUE050267T2 (hu) | 2009-02-16 | 2020-11-30 | Nogra Pharma Ltd | Alkilamido vegyületek és alkalmazásuk |
| WO2013117744A2 (en) | 2012-02-09 | 2013-08-15 | Nogra Pharma Limited | Methods of treating fibrosis |
| US9682050B2 (en) | 2012-04-18 | 2017-06-20 | Nogra Pharma Limited | Methods of treating lactose intolerance |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US9160671B2 (en) | 2012-12-03 | 2015-10-13 | Hewlett-Packard Development Company, L.P. | Ingress traffic classification and prioritization with dynamic load balancing |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| US9894013B2 (en) | 2015-02-03 | 2018-02-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Early queueing network device |
| US10567273B2 (en) * | 2015-03-27 | 2020-02-18 | Cavium, Llc | Method and apparatus for bypass routing of multicast data packets and avoiding replication to reduce overall switch latency |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017136678A1 (en) * | 2016-02-03 | 2017-08-10 | Interdigital Patent Holdings, Inc. | Methods, systems and apparatus for scheduling of subframes and hybrid automatic repeat request (harq) feedback |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| ES2993451T3 (en) | 2016-06-13 | 2024-12-30 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as inhibitors of dnmt1 |
| US11108500B2 (en) | 2016-07-05 | 2021-08-31 | Idac Holdings, Inc. | Latency reduction by fast forward in multi-hop communication systems |
| WO2018089967A1 (en) | 2016-11-14 | 2018-05-17 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| HUE057710T2 (hu) | 2017-01-23 | 2022-05-28 | Cadent Therapeutics Inc | Káliumcsatorna modulátorok |
| JP6605177B2 (ja) * | 2017-03-06 | 2019-11-13 | 三菱電機株式会社 | 転送装置、転送方法及び転送システム |
| EA039417B1 (ru) | 2017-08-07 | 2022-01-25 | Родин Терапеутикс, Инк. | Бициклические ингибиторы гистондеацетилазы |
| BR112020003725A2 (pt) | 2017-10-06 | 2020-11-03 | Forma Therapeutics, Inc. | inibição da peptidase 30 específica de ubiquitina |
| US10476815B2 (en) * | 2017-12-11 | 2019-11-12 | Ciena Corporation | Adaptive communication network with cross-point switches |
| CN112513036B (zh) | 2018-05-17 | 2024-05-24 | 福马治疗有限公司 | 用作泛素特异性肽酶30抑制剂的稠合双环化合物 |
| JP6977668B2 (ja) * | 2018-06-04 | 2021-12-08 | 日本電信電話株式会社 | 測定システム、及び測定方法 |
| CA3110113A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| JP2022508945A (ja) | 2018-10-22 | 2022-01-19 | カデント セラピューティクス，インコーポレーテッド | カリウムチャネルモジュレーターの結晶形態 |
| CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| BR112021007213A2 (pt) | 2018-10-30 | 2021-08-10 | Gilead Sciences, Inc. | derivados de quinolina como inibidores de integrina alfa4beta7 |
| ES3003232T3 (en) | 2018-10-30 | 2025-03-10 | Gilead Sciences Inc | Compounds for inhibition of alpha4beta7 integrin |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| FI3921299T3 (fi) | 2019-02-08 | 2025-02-12 | Nogra Pharma Ltd | Menetelmä 3-(4'-aminofenyyli)-2-metoksipropionihapon ja sen analogien ja välituotteiden valmistamiseksi |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
| EP4013499A1 (en) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| KR20230051127A (ko) | 2020-05-15 | 2023-04-17 | 알젠 바이오테크놀로지스, 인크. | 특정 화학 조성물 및 이의 사용 방법 |
| US11952365B2 (en) | 2020-06-10 | 2024-04-09 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12264149B2 (en) | 2020-12-30 | 2025-04-01 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| TWI789116B (zh) * | 2021-11-15 | 2023-01-01 | 瑞昱半導體股份有限公司 | 具有資料流傳輸排序機制的網格網路系統及其通訊方法 |
| KR102812054B1 (ko) | 2023-07-12 | 2025-05-23 | 아주대학교산학협력단 | 2-하이드록시-5-[[2-(2-나프탈레닐옥시)에틸]아미노]벤조산 제조공정개선 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1109180B (de) | 1953-04-16 | 1961-06-22 | Schering Ag | Verfahren zur Herstellung von Chinazolinen |
| SU1069385A1 (ru) | 1982-05-07 | 1990-11-15 | Научно-исследовательский институт фармакологии АМН СССР | Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет |
| GB9016800D0 (en) | 1990-07-31 | 1990-09-12 | Shell Int Research | Tetrahydropyrimidine derivatives |
| GB2323842A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv | Pyridine derivatives |
| CA2328396C (en) | 1998-04-20 | 2009-02-10 | Basf Aktiengesellschaft | New substituted amides, their production and their use |
| JO2308B1 (en) * | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| CA2292828A1 (en) * | 1999-12-22 | 2001-06-22 | Nortel Networks Corporation | Method and apparatus for traffic flow control in data switches |
| US6765866B1 (en) * | 2000-02-29 | 2004-07-20 | Mosaid Technologies, Inc. | Link aggregation |
| US7260104B2 (en) * | 2001-12-19 | 2007-08-21 | Computer Network Technology Corporation | Deferred queuing in a buffered switch |
| ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| US7868028B2 (en) | 2002-06-17 | 2011-01-11 | Fred Drasner | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| JP2006521357A (ja) * | 2003-03-24 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物 |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| CN1956976A (zh) | 2004-05-26 | 2007-05-02 | 詹森药业有限公司 | 作为ccr2受体拮抗剂的巯基咪唑化合物 |
| US7602712B2 (en) * | 2004-06-08 | 2009-10-13 | Sun Microsystems, Inc. | Switch method and apparatus with cut-through routing for use in a communications network |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| ES2357362T3 (es) | 2005-03-15 | 2011-04-25 | Pfizer, Inc. | Derivados de bencimidazolona como ligandos del receptor cb2. |
| CN101146811B (zh) * | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| WO2006113261A2 (en) * | 2005-04-14 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| AU2006283592A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| CN101405000A (zh) | 2006-01-19 | 2009-04-08 | 艾博特公司 | 2-亚胺基-苯并咪唑化合物 |
| JP2008013499A (ja) * | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | ５−シアノニコチンアミド誘導体 |
| AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US7843846B1 (en) * | 2006-09-18 | 2010-11-30 | Qlogic, Corporation | Method and system for processing network information |
| WO2008036244A1 (en) | 2006-09-18 | 2008-03-27 | The Burham Institute For Medical Research | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
| WO2008036882A1 (en) * | 2006-09-21 | 2008-03-27 | California Institute Of Technology | Non-metallocene organometallic complexes and related methods and systems |
| US8093246B2 (en) | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
| WO2008082487A2 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| CN104069112A (zh) | 2007-10-19 | 2014-10-01 | 贝林格尔.英格海姆国际有限公司 | 取代的哌啶子基-二氢噻吩并嘧啶 |
| AR070813A1 (es) | 2008-03-07 | 2010-05-05 | Acraf | Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1 |
| BRPI0907974A2 (pt) | 2008-03-07 | 2015-08-04 | Acraf | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças |
| KR101598931B1 (ko) | 2008-03-24 | 2016-03-02 | 신닛테츠 수미킨 가가쿠 가부시키가이샤 | 유기 전계 발광 소자용 화합물 및 이것을 이용한 유기 전계 발광 소자 |
| US20110294836A1 (en) | 2008-06-20 | 2011-12-01 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| MX2011000402A (es) | 2008-07-16 | 2011-03-15 | Astrazeneca Ab | Derivado de pirimidil sulfonamida y su uso para el tratamiento de enfermedades mediadas por quimiocinas. |
| WO2010011756A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| WO2010017350A1 (en) | 2008-08-06 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
| WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| CA2758614A1 (en) * | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| AR076550A1 (es) * | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
| EP2443106A1 (en) | 2009-06-18 | 2012-04-25 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
| WO2011029807A1 (en) | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
| RU2538200C2 (ru) * | 2009-12-28 | 2015-01-10 | Дивелэпмэнт Сентэ Фо Байэутекнолэджи | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ИХ СОДЕРЖАЩАЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| EP2736883B1 (en) | 2011-07-29 | 2019-09-04 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| CN104619687A (zh) | 2012-06-01 | 2015-05-13 | 诺格拉制药有限公司 | 能够调节t-细胞应答的双环杂环及其使用方法 |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| HRP20191430T1 (hr) | 2013-10-21 | 2019-11-01 | Merck Patent Gmbh | Spojevi heteroarila kao inhibitori btk i njihove uporabe |
-
2012
- 2012-08-01 US US13/564,118 patent/US9013997B2/en active Active
- 2012-09-12 US US13/611,252 patent/US9325637B2/en not_active Expired - Fee Related
-
2013
- 2013-05-31 ES ES13726006T patent/ES2726109T3/es active Active
- 2013-05-31 PL PL13726006T patent/PL2861575T3/pl unknown
- 2013-05-31 SI SI201331441T patent/SI2861575T1/sl unknown
- 2013-05-31 LT LTEP13726006.3T patent/LT2861575T/lt unknown
- 2013-05-31 CN CN201380033708.0A patent/CN104619691B/zh not_active Expired - Fee Related
- 2013-05-31 KR KR1020147036727A patent/KR102181914B1/ko not_active Expired - Fee Related
- 2013-05-31 HR HRP20190764 patent/HRP20190764T1/hr unknown
- 2013-05-31 CA CA2874938A patent/CA2874938C/en active Active
- 2013-05-31 DK DK13726006.3T patent/DK2861575T3/da active
- 2013-05-31 AU AU2013269551A patent/AU2013269551B2/en not_active Ceased
- 2013-05-31 WO PCT/EP2013/061330 patent/WO2013178816A1/en not_active Ceased
- 2013-05-31 JP JP2015514535A patent/JP6167173B2/ja not_active Expired - Fee Related
- 2013-05-31 HU HUE13726006A patent/HUE043201T2/hu unknown
- 2013-05-31 PT PT13726006T patent/PT2861575T/pt unknown
- 2013-05-31 US US14/404,839 patent/US10208017B2/en active Active
- 2013-05-31 BR BR112014030050A patent/BR112014030050A2/pt not_active IP Right Cessation
- 2013-05-31 EP EP13726006.3A patent/EP2861575B1/en active Active
- 2013-05-31 MX MX2014014658A patent/MX366205B/es active IP Right Grant
-
2018
- 2018-12-21 US US16/229,687 patent/US10562883B2/en not_active Expired - Fee Related
-
2019
- 2019-05-10 CY CY20191100506T patent/CY1122203T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520769A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| AR118856A2 (es) | Compuestos terapéuticos | |
| JP2014511892A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2017071634A5 (enExample) | ||
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2017537940A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| BR112015021027A2 (pt) | compostos terapêuticos | |
| JP2016510038A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2016519072A5 (enExample) | ||
| JP2016516699A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2016506958A5 (enExample) | ||
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2016503797A5 (enExample) | ||
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| JP2016505637A5 (enExample) | ||
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| WO2018075959A4 (en) | Methods using hdac11 inhibitors |